Efficacy and safety of fedratinib in patients with myelofibrosis previously treated with ruxolitinib (FREEDOM2): results from a multicentre, open-label, randomised, controlled, phase 3 trial,The Lancet Haematology

当前位置： X-MOL 学术 › Lancet Haematol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Efficacy and safety of fedratinib in patients with myelofibrosis previously treated with ruxolitinib (FREEDOM2): results from a multicentre, open-label, randomised, controlled, phase 3 trial
The Lancet Haematology ( IF 15.4 ) Pub Date : 2024-09-09 , DOI: 10.1016/s2352-3026(24)00212-6
Claire N Harrison ₁ , Ruben Mesa ₂ , Moshe Talpaz ₃ , Haifa Kathrin Al-Ali ₄ , Blanca Xicoy ₅ , Francesco Passamonti ₆ , Francesca Palandri ₇ , Giulia Benevolo ₈ , Alessandro Maria Vannucchi ₉ , Clemence Mediavilla ₁₀ , Alessandra Iurlo ₁₁ , InHo Kim ₁₂ , Shelonitda Rose ₁₃ , Patrick Brown ₁₃ , Christopher Hernandez ₁₃ , Jia Wang ₁₃ , Jean-Jacques Kiladjian ₁₄

Affiliation

Guy's and St Thomas' NHS Foundation Trust, London, UK.
Wake Forest University School of Medicine, Winston-Salem, NC, USA.
University of Michigan Cancer Center, Ann Arbor, MI, USA.
Universitätsklinikum Halle, Saale, Germany.
Institut Català d'Oncologia-Hospital Universitari Germans Trias i Pujol-Josep Carreras Leukemia Research Institute, Universitat Autònoma de Barcelona, Barcelona, Spain.
Università degli Studi di Milano, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy.
IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli", Bologna, Italy.
AOU Città de Salute e Scienza, Torino, Italy.
AOU Careggi, Universita di Firenze, Florence, Italy.
Hôpital Haut-Leveque, Bordeaux, France.
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
Seoul National University Hospital, Seoul, South Korea.
Bristol Myers Squibb, Princeton, NJ, USA.
Hospital Saint Louis and University Paris Cité, Paris, France.

Most patients with myelofibrosis develop ruxolitinib intolerance or disease that is relapsed or refractory, and survival rates after ruxolitinib discontinuation are poor. We aimed to evaluate the safety and efficacy of fedratinib versus best available therapy (BAT) in patients with myelofibrosis previously treated with ruxolitinib.

中文翻译：

fedratinib 在既往接受过 ruxolitinib 治疗的骨髓纤维化患者中的疗效和安全性（FREEDOM2）：一项多中心、开放标签、随机、对照、3 期试验的结果

大多数骨髓纤维化患者会出现 ruxolitinib 不耐受或复发或难治性疾病，并且 ruxolitinib 停药后的存活率很差。我们旨在评估 fedratinib 与最佳可用疗法（BAT）在既往接受过 ruxolitinib 治疗的骨髓纤维化患者中的安全性和有效性。

更新日期：2024-09-09

点击分享查看原文

点击收藏

阅读更多本刊新发论文